Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2024Annals of Clinical and Translational NeurologyOpen Access

CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSahla El MahdaouiGlostrup HospitalMHMarie Mathilde HansenDanish Multiple Sclerosis CenterMEMarina Rode von EssenDanish Multiple Sclerosis Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mahdaoui et al. (2024) studied this question.

synapsesocial.com/papers/68e7b3d4b6db64358770db8chttps://doi.org/10.1002/acn3.52009
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy2015 · 463 citations
  2. 2Multiple Sclerosis2018 · 2,542 citations
  3. 3Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 32013 · 139 citations
  4. 4Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity2012 · 119 citations
  5. 5Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity2011 · 845 citations